Raloxifene Hydrochloride is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds.

The global Raloxifene Hydrochloride Tablets market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Raloxifene Hydrochloride Tablets volume and value at global level, regional level and company level. From a global perspective, this report represents overall Raloxifene Hydrochloride Tablets market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Eli Lilly
Apotex Corporation
Teva Pharmaceutical
Jiangsu Hengrui Medicine
Aurobindo Pharma
Glenmark Pharmaceuticals
Sciegen Pharmaceuticals
Prasco Laboratories

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Original Drugs
Generic Drugs

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies